Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Characterization of β-cyclodextrin/myrtenol complex and its protective effect against nociceptive behavior and cognitive impairment in a chronic musculoskeletal pain model

2020; Elsevier BV; Volume: 244; Linguagem: Inglês

10.1016/j.carbpol.2020.116448

1879-1344

Luana Heimfarth, Klécia Santos dos Anjos, Yasmim Maria Barbosa Gomes de Carvalho, Bruno Lucena dos Santos, Mairim Russo Serafini, Antônio Guilherme de Carvalho Neto, Paula Santos Nunes, José Ivo Araújo Beserra Filho, Sara Pereira da Silva, Alessandra Mussi Ribeiro, Daniel P. Bezerra, Ricardo Neves Marreto, Jullyana de Souza Siqueira Quintans, Adriano Antunes de Souza Araújo, Henrique Douglas Melo Coutinho, Luciana Scotti, Luciana Scotti, Lucindo José Quintans‐Júnior,

Computational Drug Discovery Methods

Myrtenol has gained wide interest because of its pharmacological profiles, mainly for treatment of chronic diseases. To improve the solubility of myrtenol, the formation of inclusion complexes with β-cyclodextrin was performed by physical mixture, kneading process or slurry complexation (SC) methods and characterized using thermal analysis, XRD, SEM and NMR. From these results, myrtenol complexed by SC was successfully complexed into β-cyclodextrin cavity. The interaction between myrtenol and β-cyclodextrin was confirmed by molecular docking. Hence, the SC β-cyclodextrin-myrtenol complex was evaluate for its anti-hyperalgesic, anxiolytic and antioxidant activity in a fibromyalgia model. Results show that myrtenol and β-cyclodextrin form a stable complex and have anti-hyperalgesic effect, improve the cognitive impairment caused and have an anxiolytic-like effect. Furthermore, the β-cyclodextrin/myrtenol complex decrease lipoperoxidation, increased catalase activity and a reduce SOD/CAT ratio. Therefore, β-cyclodextrin/myrtenol complex reduce painful behavior, improves motor skills and emotional behavior and decreases oxidative stress in a fibromyalgia model.